Heartseed (TSE:219A) - Stock Price, News & Analysis

219A Stock Overview

Develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. More details

219A fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the JP market

Heartseed Inc. Competitors

Pharma Foods International

TSE:2929

JP¥27.1b

StemRIM

TSE:4599

JP¥21.6b

Japan Tissue Engineering

TSE:7774

JP¥20.0b

Cuorips

TSE:4894

JP¥40.4b

Price History & Performance

Summary of all time highs, changes and price drops for Heartseed
Historical stock prices
Current Share Price	JP¥1,301.00
52 Week High	JP¥1,878.00
52 Week Low	JP¥901.00
Beta	0
11 Month Change	-12.09%
3 Month Change	-18.18%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-17.66%

Recent updates

Shareholder Returns

	219A	JP Biotechs	JP Market
7D	-4.8%	0.9%	-1.1%
1Y	n/a	24.2%	11.5%

Return vs Industry: Insufficient data to determine how 219A performed against the JP Biotechs industry.

Return vs Market: Insufficient data to determine how 219A performed against the JP Market.

Price Volatility

Is 219A's price volatile compared to industry and market?
219A volatility
219A Average Weekly Movement	9.7%
Biotechs Industry Average Movement	8.5%
Market Average Movement	3.9%
10% most volatile stocks in JP Market	7.6%
10% least volatile stocks in JP Market	2.1%

Stable Share Price: 219A's share price has been volatile over the past 3 months compared to the JP market.

Volatility Over Time: Insufficient data to determine 219A's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	n/a	Keiichi Fukuda	www.heartseed.jp

Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company’s lead product candidate is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC.

Heartseed Inc. Fundamentals Summary

How do Heartseed's earnings and revenue compare to its market cap?
219A fundamental statistics
Market cap	JP¥28.62b
Earnings (TTM)	JP¥0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 219A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
219A income statement (TTM)
Revenue	JP¥0
Cost of Revenue	JP¥0
Gross Profit	JP¥0
Other Expenses	JP¥0
Earnings	JP¥0

Last Reported Earnings

n/a

Next Earnings Date

Dec 12, 2024

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 219A perform over the long term?

See historical performance and comparison

Heartseed TSE:219A Stock Report